Romosozumab for the treatment of osteoporosis
Romosozumab for the treatment of osteoporosis
复制标题
DOI：
10.1080/14712598.2017.1280455
复制
发表时间：
2017-02-01
影响因子：
4.6
通讯作者：
Bilezikian, John P.
中科院分区：
文献类型：
--
作者：
Bandeira, Leonardo;Lewiecki, E. Michael;Bilezikian, John P.
简介：硬化蛋白是一种主要由骨细胞产生的糖蛋白，可阻断经典的 Wnt 信号骨形成途径。 Romosozumab 是一种针对硬化蛋白的人源化单克隆抗体，可与硬化蛋白结合，使 Wnt 配体与其共同受体结合，从而增加骨形成和骨矿物质密度 (BMD)。 romosozumab 的临床研究显示脊柱和髋部的 BMD 显着改善。 Romosozumab 通过增加骨形成等机制与骨强度的改善相关，与经典的骨合成代谢药物不同，它抑制骨吸收。 涵盖的领域：在此，作者重点介绍了 romosozumab 用于治疗骨质疏松症的现有数据。其中包括有关疗效、药代动力学和药效学以及安全性和耐受性数据的最新数据。专家意见：每月皮下注射 romosozumab 可以降低绝经后骨质疏松症女性椎骨和临床骨折的风险，并实现利益和风险的良好平衡。 Romosozumab 是一种很有前途的新兴合成代谢药物，具有新颖的作用机制，可以扩大治疗骨折高风险骨质疏松患者的选择。
Introduction: Sclerostin, a glycoprotein produced primarily by osteocytes, blocks the canonical Wnt signaling bone formation pathway. Romosozumab is a humanized monoclonal antibody to sclerostin that binds to sclerostin, permitting the engagement of Wnt ligands with their co-receptors, resulting in an increase in bone formation and bone mineral density (BMD). Clinical studies with romosozumab have shown dramatic improvements in BMD at the spine and hip. Romosozumab is associated with improvement in bone strength through mechanisms that include increases in bone formation and, different from classical osteoanabolic agents, suppression of bone resorption.Areas covered: Herein, the authors highlight the available data on romosozumab for the treatment of osteoporosis. This includes the latest data on the efficacy, pharmacokinetics and pharmacodynamics as well as safety and tolerability data.Expert opinion: Monthly subcutaneous dosing of romosozumab reduces the risk of vertebral and clinical fractures in women with postmenopausal osteoporosis, with a favorable balance of benefits and risks. Romosozumab is a promising emerging anabolic agent with a novel mechanism of action that may expand the options for treating osteoporotic patients at high risk of fracture.